SANDYMOUNT THERAPEUTICS LTD

Active Oxford

Research and experimental development on biotechnology

0 employees website.com
Research and experimental development on biotechnology
S

SANDYMOUNT THERAPEUTICS LTD

Research and experimental development on biotechnology

Founded 16 Jul 2021 Active Oxford, England 0 employees website.com
Research and experimental development on biotechnology
Accounts Submitted 18 Dec 2025 Next due 31 Mar 2027 11 months remaining
Confirmation Submitted 15 Jul 2025 Next due 29 Jul 2026 3 months remaining
Net assets £1 £0 2024 year on year
Total assets £1 £0 2024 year on year
Total Liabilities £0
Charges None No charges registered

Contact & Details

Contact

Registered Address

Hayakawa Building, Edmund Halley Road Oxford OX4 4GB England

Telephone

0800 000 0000

Email

info@example.com

Website

www.example.com

Full company profile for SANDYMOUNT THERAPEUTICS LTD (13514842), an active company based in Oxford, England. Incorporated 16 Jul 2021. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type Total Exemption Full
Next accounts 31 December 2025
Due by 30 September 2026 9 months

Net Assets, Total Assets & Total Liabilities (2022–2024)

Cash in Bank

N/A

Net Assets

£1.00

Total Liabilities

N/A

Turnover

N/A

Employees

N/A

Debt Ratio

N/A

Financial History

Revenue, profit, EBITDA and key financial figures

2024
Dec Year End
2023
Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

No fundraising or grants recorded

Investors (0)

No investor information available

Share Capital

Share Capital

Share allotments and capital structure

1 Allotment 2,125 Shares £451.563 Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
9 Aug 20212,125£451.563£0.213

Officers

Officers

1 active 2 resigned
Status
Emma SmithDirectorBritishUnited Kingdom409 Feb 2024Active

Shareholders

Shareholders (1)

Dark Blue Therapeutics Ltd
100.0%

Persons with Significant Control

Persons with Significant Control (1)

1 Active
Active
Notified 16 Jul 2021
Nature of Control
  • Ownership Of Shares 75 To 100 Percent,voting Rights 75 To 100 Percent,right To Appoint And Remove Directors

Group Structure

Group Structure

SANDYMOUNT THERAPEUTICS LTD Current Company

Charges

Charges

No charges registered

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
7 Jan 2026OfficersAppointment of Mr Russell James Abberley as director on 2025-12-30
6 Jan 2026OfficersTermination of Alastair Graham Mackinnon as director on 2025-12-30
5 Jan 2026OfficersTermination of Emma Smith as director on 2025-12-30
5 Jan 2026OfficersAppointment of Mr Christopher Paul Walker as director on 2025-12-30
18 Dec 2025AccountsAnnual accounts made up to 2025-06-30
7 Jan 2026 Officers

Appointment of Mr Russell James Abberley as director on 2025-12-30

6 Jan 2026 Officers

Termination of Alastair Graham Mackinnon as director on 2025-12-30

5 Jan 2026 Officers

Termination of Emma Smith as director on 2025-12-30

5 Jan 2026 Officers

Appointment of Mr Christopher Paul Walker as director on 2025-12-30

18 Dec 2025 Accounts

Annual accounts made up to 2025-06-30

Recent Activity

Latest Activity

Appointment of Mr Russell James Abberley as director on 2025-12-30

3 months ago on 7 Jan 2026

Termination of Alastair Graham Mackinnon as director on 2025-12-30

3 months ago on 6 Jan 2026

Termination of Emma Smith as director on 2025-12-30

3 months ago on 5 Jan 2026

Appointment of Mr Christopher Paul Walker as director on 2025-12-30

3 months ago on 5 Jan 2026

Annual accounts made up to 2025-06-30

4 months ago on 18 Dec 2025